Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $12.67 USD
Change Today +0.1168 / 0.93%
Volume 264.2K
VNDA On Other Exchanges
Symbol
Exchange
Frankfurt
As of 2:18 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Richard W. Dugan

Independent Director, Chairman of Audit Committee and Member of Nominating/Corporate Governance Committee, Vanda Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 12 board members in 2 different organizations across 2 different industries.

See Board Relationships
73$151,250

Background*

Mr. Richard W. Dugan served as a Partner of Ernst & Young LLP, from 1976 to September 2002. Mr. Dugan served in a variety of managing and senior partner positions at Ernst & Young LLP, including Mid-Atlantic Area Senior Partner from 2001 to 2002, Mid-Atlantic Area Managing Partner from 1989 to 2001 and Pittsburgh Office Managing Partner from 1981 to 1989. He retired from Ernst & Young LLP in September 2002. Mr. Dugan has been an Independent Director at Vanda Pharmaceuticals, ...

Read Full Background

Corporate Headquarters*

2200 Pennsylvania Avenue NW
Washington, District Of Columbia 20037

United States

Phone: 202-734-3400
Fax: 202-296-1450

Board Members Memberships*

Former Director
2003-2010
Former Director, Chairman of Audit Committee and Member of Compensation Committee
2004-N/A
Former Lead Independent Director, Chairman of Audit Committee and Member of Nominating & Corporate Governance Committee
2005-N/A
Former Director
2005-Present
Independent Director, Chairman of Audit Committee and Member of Nominating/Corporate Governance Committee

Education*

BSBA
Pennsylvania State University

Other Affiliations*

Annual Compensation*

There is no Annual Compensation data available.

Stock Options*

Exercisable Options124,323
Unexercisable Options6,251
Total Number of Options130,574

Total Compensation*

Total Annual Cash Compensation$61,250
Total Calculated Compensation$151,250
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $12.67 USD +0.1168

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Giovanni Caforio M.D.Chief Executive Officer and Director
Bristol-Myers Squibb Company
$916.0K
John C. Lechleiter Ph.D.Chairman, Chief Executive Officer and President
Eli Lilly and Company
$1.5M
Pascal Soriot Chief Executive Officer, Executive Director and Member of Disclosure Committee
AstraZeneca PLC
3.1M GBP
Olivier Brandicourt Chief Executive Officer and Director
Sanofi
--
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
$814.6K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.